Expansion for Ultrafine
Ultrafine has started construction of an additional facility to
expand its capabilities in the custom manufacturing of active
pharmaceutical ingredients (APIs) and intermediates.
Bayer to split down the middle
The long-awaited break-up of Germany's Bayer has finally come to
pass with the decision to float the group's chemicals business on
the stock exchange within the next 18 months. But will this be the
end of the story for the...
Malvern buys rheology firm
Particle testing specialist Malvern Instruments has acquired
Bohlin, which focuses on the development and manufacture of
rheology systems; also sells PharmaVision 380 system to Altana.
More consolidation in RNAi
Invitrogen has acquired fellow US firm Sequitur in a move that
bolsters its technology portfolio in RNA interference (RNAi) and
marks a continuing trend towards consolidation in this sector.
Dissecting the bioprocessing market with D&MD
The global market for bioprocessing is mirroring the phenomenal
growth of the biotechnology industry around the world, says a
recently-published report from D&MD Reports.
Fine chemicals hit hard at Pliva
Eastern European company Pliva has reported a 20 per cent hike in
sales for the third quarter of 2003 that concealed a major
contraction in the firm's fine chemicals business.
Pressure still on at Degussa
Degussa sees no signs of any let-up in the difficulties facing the
chemicals industry in the third quarter, with both sales and pretax
earnings continuing to slide.
New pMDI facility opens at Bespak
Bespak of the UK, a specialist in inhalation devices for drug
delivery, has opened a new £10 million (€15m) facility at its
King's Lynn site for the manufacture of pMDIs.
Aventis seeks time for Rhodia sale
Franco-German drugmaker Aventis has confirmed that it is seeking to
delay the divestment of its stake in the loss-making chemicals
major Rhodia, on the grounds that this willwreak havoc on the
latter's restructuring drive.
Fine chemicals revamp completes at Degussa
The completion of Degussa's reorganisation of its fine chemicals
activities into two separate business units heralds a raft of new
projects at the company.
Mettler Toledo holds up in 3Q
Instruments specialist Mettler Toledo reports flat sales in a
difficult operating environment for the sector, but says that
investments in R&D should pay off going forward.
CIMA ditches aaiPharma for Cephalon
Cephalon is to acquire CIMA Laboratories, best known for its
dissolve-on-the-tongue tablet technology, for $515 million (€449m)
Bayer Chemicals launches into turbulent seas
Bayer Chemicals became a separate legal entity from the rest of the
Bayer group just over one month ago, having operated as a virtual
company since the middle of 2002. The company gave its first press
conference at the CPhI meeting...
Net loss in 3Q for Flamel
Flamel Technologies dips back into loss in the third quarter but
expects to be cash-flow positive for the year as a whole. License
and research revenues rise to $4.2m.
Teva takes Sicor to the altar
Israel's Teva plans to buy Sicor in a €2.9bn deal that will create
a powerhouse in generic pharmaceuticals and active pharmaceutical